Gerresheimer saw the highest growth of 1.32% in patent filings in May and 1.66% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.29% and grants by 1.66%. GlobalData’s DataBook provides a comprehensive analysis of Gerresheimer‘s patent filings and grants. Buy the databook here.
Gerresheimer has been focused on protecting inventions in European Patent Office(EPO) with ten publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 41% filings and 4% grants. The European Patent Office(EPO), United States(US), Canada(CA), and China(CN) patent Office are among the top ten patent offices where Gerresheimer is filings its patents. Among the top granted patent authorities, Gerresheimer has 17% of its grants in United States(US), 17% in China(CN) and 17% in Spain(ES).
Becton Dickinson and Co and Amgen could be the strongest competitors for Gerresheimer
Patents related to climate change and nanomedicine lead Gerresheimer's portfolio
Gerresheimer has the highest number of patents in climate change followed by, nanomedicine and industrial automation. For climate change, nearly 60% of patents were filed and no patents were granted in Q2 2024.
Drug delivery devices related patents lead Gerresheimer portfolio followed by packaging, and manufacturing/industrial
Gerresheimer has highest number of patents in drug delivery devices followed by packaging, manufacturing/industrial, bottled water, and pharmaceutical & healthcare packaging. For drug delivery devices, nearly 50% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Gerresheimer's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.